RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Aeterna Zentaris - Stock

Aeterna Zentaris ROA 2024

Aeterna Zentaris ROA

-0.45

Ticker

AEZS.TO

ISIN

CA0079754028

WKN

A1439Z

In 2024, Aeterna Zentaris's return on assets (ROA) was -0.45, a 10.31% increase from the -0.41 ROA in the previous year.

Aeterna Zentaris Aktienanalyse

What does Aeterna Zentaris do?

Aeterna Zentaris Inc. is a Canadian company that has been operating in the pharmaceutical industry since 1991. The company is headquartered in Quebec City, Canada and focuses on the development and commercialization of drugs for the treatment of cancer and hormonal disorders. The company started as a small biotech company called "Aeterna Laboratories" that focused on the research of growth hormones and hormonal disorders. In the late 90s, it merged with a German company called "Zentaris GmbH" that specialized in medical diagnostics and chemicals, creating Aeterna Zentaris AG, which was later renamed Aeterna Zentaris Inc. The company has acquired several companies and expanded its portfolio of drugs and treatment options. Aeterna Zentaris is a biopharmaceutical company engaged in preclinical and clinical development of therapeutics. The company's main strategy is to develop and promote innovative and differentiating drug candidates. It works closely with leading academic institutions, researchers, and other companies to advance the development of its products. Aeterna Zentaris has a diversified portfolio of drug candidates in various stages of clinical development. It has two main divisions: cancer treatment and hormonal disorders. The company focuses on developing cancer therapeutics for various types of cancers and also on the treatment of hormonal disorders, including diabetes, growth problems, hormonally related cancers, and menopause. Some of the company's important products include Macrilen, which is used for diagnosing growth hormone deficiency, Zoptrex, which is intended for the treatment of endometrial cancer, and Perifosine, a drug candidate for advanced colorectal cancer. Aeterna Zentaris has established itself as a leading biotech company in the field of cancer and hormone therapy. It has a diverse portfolio of drug candidates in different stages of clinical development. The company collaborates with researchers, medical institutions, and other companies to develop innovative and differentiating drug candidates. Aeterna Zentaris ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Aeterna Zentaris's Return on Assets (ROA)

Aeterna Zentaris's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Aeterna Zentaris's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Aeterna Zentaris's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Aeterna Zentaris’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Aeterna Zentaris Stock

What is the Return on Assets (ROA) of Aeterna Zentaris this year?

The Return on Assets (ROA) of Aeterna Zentaris is -0.45 undefined this year.

What was the ROA of Aeterna Zentaris compared to the previous year?

The ROA of Aeterna Zentaris has increased by 10.31% compared to the previous year.

What consequences do high ROA have for investors of Aeterna Zentaris?

A high ROA is advantageous for investors of Aeterna Zentaris, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Aeterna Zentaris?

A low ROA can be unfavorable for investors of Aeterna Zentaris as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Aeterna Zentaris affect the company?

An increase in ROA of Aeterna Zentaris can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Aeterna Zentaris impact the company?

A reduction in the ROA of Aeterna Zentaris can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Aeterna Zentaris?

Some factors that can influence the ROA of Aeterna Zentaris include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Aeterna Zentaris important for investors?

The ROA of Aeterna Zentaris is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Aeterna Zentaris take to improve ROA?

To improve ROA, Aeterna Zentaris can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Aeterna Zentaris pay?

Over the past 12 months, Aeterna Zentaris paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Aeterna Zentaris is expected to pay a dividend of 0 USD.

What is the dividend yield of Aeterna Zentaris?

The current dividend yield of Aeterna Zentaris is .

When does Aeterna Zentaris pay dividends?

Aeterna Zentaris pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Aeterna Zentaris?

Aeterna Zentaris paid dividends every year for the past 0 years.

What is the dividend of Aeterna Zentaris?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Aeterna Zentaris located?

Aeterna Zentaris is assigned to the 'Health' sector.

Wann musste ich die Aktien von Aeterna Zentaris kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Aeterna Zentaris from 7/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/1/2024.

When did Aeterna Zentaris pay the last dividend?

The last dividend was paid out on 7/1/2024.

What was the dividend of Aeterna Zentaris in the year 2023?

In the year 2023, Aeterna Zentaris distributed 0 USD as dividends.

In which currency does Aeterna Zentaris pay out the dividend?

The dividends of Aeterna Zentaris are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Aeterna Zentaris stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Aeterna Zentaris

Our stock analysis for Aeterna Zentaris Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Aeterna Zentaris Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.